Fosphenytoin/Selected QT Prolongers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Fosphenytoin can affect your heart's rhythm. Other drugs can have the same effect.
What might happen:
Taking fosphenytoin with other agents that can affect your heart rhythm may increase your risk of an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g doctor or pharmacist) know that you are taking these medications together. Your doctor may want to perform an electrocardiogram (ECG) on you to check your heart's rhythm. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes. Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Uroxatral (alfuzosin hydrochloride) US prescribing information. Sanofi-Synthelabo, Inc. December, 2010.
2.Apokyn (apomorphine hydrochloride) US prescribing information. Tercica, Inc. July, 2010.
3.Clozaril (clozapine tablets) US prescribing information. Novartis Pharmaceuticals Corporation October, 2011.
4.Anzemet (dolasetron mesylate) US prescribing information. Sanofi-Aventis Us.S. LLC September, 2011.
5.Mathivanan M. Dear Canadian Healthcare Professional: Subject: Association of domperidone maleate with serious ventricular arrhythmias and sudden cardiac death. Teva Canada Limited March 2, 2012.
6.Foradil Aerolizer (formoterol fumarate) US prescribing information. Schering Corporation September, 2012.
7.Symbicort Turbuhaler (budesonide-eformoterol fumarate dihydrate) Australian prescribing information. AstraZeneca Pty Ltd April 30, 2004.
8.Primovist (gadoxetate disodium) Australian prescribing information. Schering-Plough Corporation November 1, 2005.
9.Primovist (gadoxetic acid) UK summary of product characteristics. Bayer plc May 1, 2008.
10.Tequin (gatifloxacin) US prescribing information. Bristol-Myers Squibb Company January, 2006.
11.Factive (gemifloxacin mesylate) US prescribing information. Oscient Pharmaceuticals October, 2011.
12.Serenace (haloperidol) Australian prescribing information. Sigma Pharmaceuticals Pty Ltd. June 5, 2001.
13.Dozic (haloperidol) UK summary of product characteristics. Rosemont Pharmaceuticals Limited September 10, 2007.
14.Haldol (haloperidol) US prescribing information. Ortho-McNeil-Janssen Pharmaceuticals, Inc. August, 2011.
15.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline February, 2012.
16.Levaquin (levofloxacin) US prescribing information. Ortho-McNeil Pharmaceutical, Inc. Apil, 2012.
17.Dolophine (methadone hydrochloride) US prescribing information. Roxane Laboratories, Inc. July, 2012.
18.Avelox (moxifloxacin hydrochloride) US prescribing information. Bayer Pharmaceuticals Corporation August, 2012.
19.NegGram (nalidixic acid) US prescribing information. Sanofi-Synthelabo, Inc. November, 2012.
20.Noroxin (norfloxacin) US prescribing information. Merck & Co., Inc. March, 2013.
21.Aloxi (polonosetron hydrochloride) US prescribing information. MGI Pharma September, 2007.
22.Risperidal (risperidone) UK summary of product characteristics. Janssen-Cilag, UK Limited May 14, 2004.
23.Zolinza (vorinostat) US prescribing information. Merck & Co., Inc. 2006.
24.Trisenox (arsenic trioxide) US prescribing information. Cell Therapeutics, Inc. March, 2001.
25.Sirturo (bedaquiline) US prescribing information. Janssen Therapeutics December, 2012.
26.FDA. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. available at: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm March 28, 2012.
27.Halaven (eribulin mesylate) US prescribing information. Eisai, Inc. November, 2010.
28.Trobalt (retigabine) UK summary of product characteristics. GlaxoSmithKline UK March 28, 2011.
29.Ablavar (gadofosveset trisodium) US prescribing information. Lantheus Medical Imaging, Inc. December, 2010.
30.Zofran (ondansetron) US prescribing information. GlaxoSmithKline November, 2012.
31.Anonymous. FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron). available at: http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm September 15, 2011.
32.Signifor (pasireotide diasparate) US prescribing information. Novartis Pharmaceuticals Corporation December, 2012.
33.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.
34.Nexavar (sorafenib) US prescribing information. Bayer Pharmaceuticals Corporation August, 2012.
35.Fareston (toremifene citrate) US prescribing information. GTx, Inc. March, 2011.
36.Fareston (toremifene citrate) UK summary of product characteristics. Orion Pharma (UK) Limited January, 2009.
37.Caprelsa (vandetanib) US prescribing information. AstraZeneca Pharmaceuticals LP October, 2012.
38.Zelboraf (vemurafenib) US Prescribing Information. Hoffman-La Roche August, 2011.
39.Tikosyn (dofetilide) US prescribing information. Pfizer Inc. February, 2011.
40.Rythmol (propafenone hydrochloride) US prescribing information. Abbott Laboratories March, 2013.
41.Betapace (sotalol hydrochloride) US prescribing information. Berlex Laboratories August, 2011.
42.Qualaquin (quinine sulfate) US prescribing information. AR Scientific, Inc. February, 2013.
43.Vibativ (telavancin) US prescribing information. Astellas Pharma US, Inc. September, 2009.
44.Saphris (asenapine) US prescribing information. Schering Corporation October, 2011.
45.Fanapt (iloperidone) US prescribing information. Novartis Pharmaceuticals Inc January, 2013.
46.Procoralan (ivabradine hydrochloride) summary of product characteristics. Servier December, 2005.
47.Serentil (mesoridazine besylate) US prescribing information. Novartis Pharmaceuticals Corporation August, 2000.
48.Invega (paliperidone) US prescribing information. Janssen Pharmaceuticals, Inc. April, 2011.
49.Xenazine (tetrabenazine) US prescribing information. Ovation Pharmaceuticals, Inc. September, 2008.
50.Javlor (vinflunine ditartrate) UK Summary of Product Characteristics. Pierre Fabre Limited September 21, 2009.
51.Clopixol (zuclopenthixol acetate) UK summary of product characteristics. Lundbeck House October 24, 2008.
52.The University of Arizona Center for Education and Research of Therapeutics. Drugs with Risk of Torsades de Pointes and Drugs with Possible Risk of Torsades de Pointes. Available at:http://www.crediblemeds.org/. Updated March 14, 2013.
